Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac safety of Caelyx in anthracycline-pretreated metastatic breast cancer
2004-001177-25Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2004
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegylated liposomal doxorubicin in breast cancer, sponsored by Merck & Co. Primary endpoint: Cardiac event based on change in LVEF. Started Dec 2004; status: terminated.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-001177-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001177-25.